- |||||||||| pioglitazone / Generic mfg.
Trial completion date, Trial primary completion date: PAUSE: Pioglitazone for the Treatment of Alcohol Use Disorder (clinicaltrials.gov) - Jan 26, 2023
P=N/A, N=200, Recruiting,
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Jan 2023 --> Dec 2023
- |||||||||| metformin / Generic mfg.
Journal: Combining Metformin and Drug-Loaded Kidney-Targeting Micelles for Polycystic Kidney Disease. (Pubmed Central) - Jan 21, 2023
Together, we show drug synergy using drug-loaded nanoparticles and free MET for the first time and present a novel nanomedicine-based combinatorial therapeutic approach for ADPKD with enhanced efficacy. The online version contains supplementary material available at 10.1007/s12195-022-00753-9.
- |||||||||| pioglitazone / Generic mfg.
Preclinical, Journal: Protective Effect of Pioglitazone on Retinal Ganglion Cells in an Experimental Mouse Model of Ischemic Optic Neuropathy. (Pubmed Central) - Jan 9, 2023
Furthermore, microglial cell infiltration in the retina (group 1: 2.0 ± 2.6 cells/field; group 2: 15.6 ± 3.5 cells/field; and group 3: 14.8 ± 7.5 cells/field) and retinal thinning (group 1: 6.7 ± 5.7 μm; group 2: 12.8 ± 6.1 μm; and group 3: 15.8 ± 5.8 μm) were also lower in group 1 than in the other two groups. In non-diabetic mice, preserved Brn3A cells were significantly greater in group 2 (2382 ± 140 Brn3A+ cells/mm, n = 7) than in group 1 (1920 ± 228 Brn3A+ cells/mm; p = 0.03, n = 4), group 3 (1938 ± 213 Brn3A+ cells/mm; p = 0.002, n = 4), and group 4 (2138 ± 126 Brn3A+ cells/mm; p = 0.03, n = 4), respectively; PGZ confers protection to RGCs from damage caused by ischemic optic neuropathy in diabetic and non-diabetic mice.
- |||||||||| pioglitazone / Generic mfg.
Retrospective data, Review, Journal: Change in left ventricular diastolic function after pioglitazone treatment in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis. (Pubmed Central) - Jan 7, 2023
In non-diabetic mice, preserved Brn3A cells were significantly greater in group 2 (2382 ± 140 Brn3A+ cells/mm, n = 7) than in group 1 (1920 ± 228 Brn3A+ cells/mm; p = 0.03, n = 4), group 3 (1938 ± 213 Brn3A+ cells/mm; p = 0.002, n = 4), and group 4 (2138 ± 126 Brn3A+ cells/mm; p = 0.03, n = 4), respectively; PGZ confers protection to RGCs from damage caused by ischemic optic neuropathy in diabetic and non-diabetic mice. Pioglitazone treatment significantly improved left ventricular diastolic function in type 2 diabetic patients with a mean age of < 55 years, but did not improve left ventricular diastolic function in patients with a mean age of ≥ 55 years.
- |||||||||| pioglitazone / Generic mfg., nitroglycerin / Generic mfg.
ULTRASOUND-ENHANCED DEEP ARTERIAL WALL THERAPEUTIC DELIVERY (Interventional and Structural Moderated Poster Theater 2_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_2652;
A fibrin-binding peptide conjugated to dinitrophenyl (DNP)-labeled pioglitazone loaded into biotinylated echogenic liposomes (PAFb-DNP-PGN-bELIP) for fluorescent immunohistochemical (IHC) imaging of both drug and carrier was delivered to balloon-injured segments of porcine carotid arteries after nitroglycerin (NTG) pretreatment. This study confirms full thickness ultrasound-enhanced pioglitazone delivery with the potential to stabilize neointimal hyperplasia and the total arterial wall at the time of arterial intervention.
- |||||||||| pioglitazone / Generic mfg.
Review, Journal: Diabetes and Stroke: What Are the Connections? (Pubmed Central) - Jan 3, 2023
The diabetes medications pioglitazone and glucagon-like peptide-1 receptor agonists have demonstrated protection against stroke in randomized controlled trials; this protective effect is believed to be independent of glycemic control...This review provides an overview of the relationships between diabetes and stroke, including epidemiology, pathophysiology, post-stroke outcomes, and treatments for people with stroke and diabetes. This should aid neurologists in diabetes-related decision-making when treating people with acute or recurrent stroke.
- |||||||||| pioglitazone / Generic mfg.
Trial completion date, Trial primary completion date: IUAN: Pathophysiology of Uric Acid Nephrolithiasis (clinicaltrials.gov) - Dec 28, 2022
P=N/A, N=60, Recruiting,
PPARα/γ synergism treated obesity by ameliorating the gut-adipose tissue axis, where restored gut microbiota and permeability controlled endotoxemia and rescued iBAT whitening through favored thermogenesis. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
- |||||||||| pioglitazone / Generic mfg.
Journal: Regulatory Effects and Mechanism of Action of Green Tea Polyphenols on Osteogenesis and Adipogenesis in Human Adipose Tissue-Derived Stem Cells. (Pubmed Central) - Dec 23, 2022
We found that GTPs treatment significantly decreased lipid accumulation and cellular triglyceride synthesis in mature adipocytes and attenuated pioglitazone-induced adipogenesis in a dose-dependent manner...In conclusion, our data demonstrates GTPs possesses great ability to facilitate osteogenesis and simultaneously inhibits hADSC differentiation into adipogenic lineage by upregulating the RUNX2-BMP2 mediated osteogenic pathway and suppressing PPARγ-induced signaling of adipogenesis. These findings highlight GTPs' potential to combat osteoporosis associated with obesity.
- |||||||||| hyoscine butylbromide oral / Generic mfg., pioglitazone / Generic mfg.
Preclinical, Journal: PPARγ activation improved learning and memory and attenuated oxidative stress in the hippocampus and cortex of aged rats. (Pubmed Central) - Dec 22, 2022
In the current research, the effect of PPARγ activation by pioglitazone(Pio) on learning, memory and oxidative stress was evaluated in aged rats...In the Control group, vehicle (saline-diluted dimethyl sulfoxide (DMSO)) and saline were injected instead of Pio and scopolamine (Sco), respectively...Pio especially, in the medium and highest doses, decreased MDA while increasing thiol, superoxide dismutase, and catalase in the hippocampus and cortex. It is concluded that PPARγ activation by Pio as an agonist improved learning and memory in aged rats probably by attenuating oxidative stress in the hippocampus and cortex.
- |||||||||| metformin / Generic mfg., pioglitazone / Generic mfg., clomifene citrate / Generic mfg.
Preclinical, Journal: Does Pten have an impact on oogenesis of PCOS mouse models? (Pubmed Central) - Dec 20, 2022
This study is important as it shows the expression patterns of two genes in PCOS mouse models with different treatment strategies, including clomiphene citrate, metformin and pioglitazone. The results of this study formed the basis of research studies and investigations into different genes within the PTEN pathway, as well as other pathways that are under investigation.
- |||||||||| pioglitazone / Generic mfg.
Journal: Rational Design of a New RXR Agonist Scaffold Enabling Single-Subtype Preference for RXRα, RXRβ, and RXRγ. (Pubmed Central) - Dec 20, 2022
Molecular modeling indicated different binding conformations and interaction patterns with the RXR LBDs as factors of preferential binding. In a phenotypic adipocyte differentiation experiment, only the RXRα preferential tool enhanced the adipogenic effects of pioglitazone, suggesting this subtype as particularly relevant in adipogenesis and highlighting the set of subtype-preferential RXR agonist tools as suitable for functional cellular studies.
- |||||||||| Ocaliva (obeticholic acid) / Intercept, lanifibranor (IVA337) / Inventiva
Pharmacotherapy: Past and Current (2F Room 201ABC) - Dec 18, 2022 - Abstract #APASL2023APASL_220;
Although there is currently no licensed treatment for metabolic dysfunction-associated fatty liver disease, guidelines support the use of vitamin E, pioglitazone or glucagon-like peptide-1 receptor agonists in selected patients with steatohepatitis...In the interim Week 72 histological assessment of the phase 3 REGERNATE study, obeticholic acid at a dose of 25 mg daily improved liver fibrosis with no worsening of steatohepatitis...Lanifibranor, a pan-PPAR agonist, was shown to both resolve steatohepatitis and improve fibrosis in a phase 2b study. Because the pathogenesis of steatohepatitis is complicated and heterogeneous, it is believed that precision medicine and combination treatments will be needed.
- |||||||||| pioglitazone / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist. (Pubmed Central) - Nov 27, 2022
In addition, PGZ likely reverts premature senescence phenotype. In summary, the results outline a novel mode of action of Pioglitazone, which may turn out to be relevant to the development of effective new vitiligo therapeutic strategies.
- |||||||||| Clinical, Review, Journal: Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. (Pubmed Central) - Nov 25, 2022
There is a direct association between craving and cocaine use, underscoring craving as an important treatment target for promoting abstinence among persons with cocaine use disorder. Clonidine, fenfluramine and m-CPP showed to be promising medications for cocaine craving in the short-term treatment, and amphetamine, biperiden, carbamazepine, lisdexamfetamine, lorcaserin, methamphetamine, mirtazapine, pioglitazone, progesterone, guanfacine, levodopa, nefazodone in the long-term treatment.
- |||||||||| etomoxir (MIQ-001) - Meta / IQ
Journal: A screen of small molecule and genetic modulators of life span in female Drosophila identifies etomoxir, RH5849 and unanticipated temperature effects. (Pubmed Central) - Nov 23, 2022
Mifepristone increases life span in female Drosophila melanogaster, and its molecular target(s) remain unclear...Pioglitazone is reported to activate both mammalian PPARγ and its Drosophila homolog Eip75B...Even when applied after mating was complete, a shift to 29°C temperature reduced mating-induced midgut hypertrophy by half, and the life span effects of mating by 4.8-fold. Taken together, these results identify promising small molecules for further analysis, and inform the design of experiments involving the GAL4/GAL80ts system.
- |||||||||| pioglitazone / Generic mfg.
Preclinical, Journal: Peroxisome proliferator-activated receptor-γ doesn't modify altered electrophysiological properties of the CA1 pyramidal neurons in a rat model of hepatic cirrhosis. (Pubmed Central) - Nov 22, 2022
The effects of pioglitazone on BDL-induced electrophysiological alterations of the CA1 pyramidal neurons in the hippocampus were evaluated by whole-cell patch clamp recordings. Our findings demonstrated that chronic administration of PIO could not reverse the electrophysiological changes in the CA1 pyramidal neurons of the hippocampus in BDL rats but could improve the hepatic dysfunction.Together, the results of this study suggest that PIO administration cannot counteract altered intrinsic properties of the hippocampal neurons which has been shown recently as an involved mechanism of the cognitive impairments in hepatic encephalopathy (HE).
- |||||||||| pioglitazone / Generic mfg.
Retrospective data, Review, Journal: Pioglitazone use is associated with reduced risk of Parkinson's disease in patients with diabetes: A systematic review and meta-analysis. (Pubmed Central) - Nov 22, 2022
Our findings demonstrated that chronic administration of PIO could not reverse the electrophysiological changes in the CA1 pyramidal neurons of the hippocampus in BDL rats but could improve the hepatic dysfunction.Together, the results of this study suggest that PIO administration cannot counteract altered intrinsic properties of the hippocampal neurons which has been shown recently as an involved mechanism of the cognitive impairments in hepatic encephalopathy (HE). Pioglitazone administration in PD in diabetes patients is significantly associated with a decrease in the risk of PD.
- |||||||||| Journal: Drugs for type 2 diabetes. (Pubmed Central) - Nov 18, 2022
Pioglitazone intake is effective in nonalcoholic steatohepatitis management. No abstract available
- |||||||||| pioglitazone / Generic mfg.
Journal: Alternatively Spliced Landscape of PPARγ mRNA in Podocytes Is Distinct from Adipose Tissue. (Pubmed Central) - Nov 16, 2022
Traditional agonists (e.g., pioglitazone) and selective modulators (e.g., GQ-16) of peroxisome-proliferator-activated-receptor-γ (PPARγ) reduce proteinuria in animal models of glomerular disease and protect podocytes from injury via PPARγ activation...In summary, podocytes and glomeruli express several PPARγ variants, including Var1 (γ1) and excluding adipocyte-specific Var2 (γ2), which may have implications in podocyte specific signaling and pathophysiology. This suggests that that new selective PPARγ modulators can be potentially developed that will be able to distinguish between the two forms, γ1 and γ2, thus forming a basis of novel targeted therapeutic avenues.
|
